ERBB2 and breast cancer: Our preliminary studies have suggested that the presence of HER2-low CTCs (1+) has a negative prognostic value in Stage IVAggressive (CTCs ≥ 5 in 7.5 mL) breast cancer patients and that it is associate with a peculiar metastatic behavior.